Belite Bio, Inc
BLTE
शेयरों में रैंक
#2952
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
शेयर मूल्य
$152.78
अंतिम समन्वयन: 2026-10-21
मार्केट कैप
$6.15B
बदलाव (1 दिन)
-1.08%
बदलाव (1 वर्ष)
70.97%
देश
US
व्यापार Belite Bio, Inc (BLTE)
श्रेणी
Healthcare
Belite Bio, Inc (BLTE) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $154.24 (2026-10-01 को)
दिन का सबसे निम्न समापन मूल्य: $10.59 (2022-04-01 को)
दिन का सबसे निम्न समापन मूल्य: $10.59 (2022-04-01 को)
Belite Bio, Inc के स्टॉक मूल्य का इतिहास 2022 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
| वर्ष | प्रदर्शन |
|---|---|
| 2026 (TTM) | 1.34% |
| 2025 | 137.93% |
| 2024 | 45.90% |
| 2023 | 43.40% |
| 2022 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
| कंपनी | स्टॉक मूल्य | परिवर्तन 1व% | देश |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.73 | 7.70% |
CH
|
